Floatz logo

Elbasvir

Hepatitis C

Bayside HealthSmall moleculePhase 4 / ApprovedDormant
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Hepatitis C cohort.

Asset / SponsorPhaseRating
PARITAPREVIR
AbbVie
Phase 4A
Daclatasvir
MTI University
Phase 4A
Velpatasvir
Peking University People's Hospital
Phase 4A
GLECAPREVIR
AbbVie
Phase 3A
Abt-530
AbbVie
Phase 3A

View all 50 →

Same molecule, other indications

Elbasvir is also rated in:

chronic hepatitis C virus infectionDormant
BBB
Indicative ·
72 / 100
View asset →
cirrhosis of liverDormant
BBB
Indicative ·
72 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →